$15.64
4.75% yesterday
Nasdaq, Dec 30, 10:06 pm CET
ISIN
US4923271013
Symbol
KROS
Sector
Industry

Keros Therapeutics Inc Target price 2024 - Analyst rating & recommendation

Keros Therapeutics Inc Classifications & Recommendation:

Buy
79%
Hold
21%

Keros Therapeutics Inc Price Target

Target Price $43.55
Price $15.64
Potential
Number of Estimates 11
11 Analysts have issued a price target Keros Therapeutics Inc 2025 . The average Keros Therapeutics Inc target price is $43.55. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 14 analysts: 11 Analysts recommend Keros Therapeutics Inc to buy, 3 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Keros Therapeutics Inc stock has an average upside potential 2025 of . Most analysts recommend the Keros Therapeutics Inc stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 0.15 0.55
268.87%
EBITDA Margin -112,753.33% -36,931.17%
67.25%
Net Margin -136,101.33% -36,703.39%
73.03%

12 Analysts have issued a sales forecast Keros Therapeutics Inc 2024 . The average Keros Therapeutics Inc sales estimate is

$553k
Unlock
. This is
14.88% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$1.0m 55.08%
Unlock
, the lowest is
$100k 84.62%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $150k
2024
$553k 268.87%
Unlock
2025
$3.8m 593.57%
Unlock
2026
$15.0m 289.58%
Unlock
2027
$13.2m 11.55%
Unlock
2028
$71.5m 440.43%
Unlock

1 Analyst has issued an EBITDA forecast Keros Therapeutics Inc 2024 . The average Keros Therapeutics Inc EBITDA estimate is

$-204m
Unlock
. This is
0.72% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-204m 0.72%
Unlock
, the lowest is
$-204m 0.72%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-169m 49.43%
2024
$-204m 20.83%
Unlock
2025
$-224m 9.57%
Unlock

EBITDA Margin

2023 -112,753.33%
2024
-36,931.17% 67.25%
Unlock
2025
-5,834.83% 84.20%
Unlock

10 Keros Therapeutics Inc Analysts have issued a net profit forecast 2024. The average Keros Therapeutics Inc net profit estimate is

$-203m
Unlock
. This is
0.71% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-187m 8.64%
Unlock
, the lowest is
$-216m 5.57%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-204m 25.30%
2024
$-203m 0.52%
Unlock
2025
$-208m 2.48%
Unlock
2026
$-185m 10.88%
Unlock
2027
$-210m 12.99%
Unlock
2028
$-195m 6.84%
Unlock

Net Margin

2023 -136,101.33%
2024
-36,703.39% 73.03%
Unlock
2025
-5,423.69% 85.22%
Unlock
2026
-1,240.64% 77.13%
Unlock
2027
-1,584.97% 27.75%
Unlock
2028
-273.23% 82.76%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -5.20 -5.17
25.30% 0.58%
P/E negative
EV/Sales 277.84

10 Analysts have issued a Keros Therapeutics Inc forecast for earnings per share. The average Keros Therapeutics Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-5.17
Unlock
. This is
0.77% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-4.76 8.64%
Unlock
, the lowest is
$-5.50 5.57%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-5.20 25.30%
2024
$-5.17 0.58%
Unlock
2025
$-5.30 2.51%
Unlock
2026
$-4.72 10.94%
Unlock
2027
$-5.34 13.14%
Unlock
2028
$-4.97 6.93%
Unlock

P/E ratio

Current -3.15 59.25%
2024
-3.17 0.63%
Unlock
2025
-3.10 2.21%
Unlock
2026
-3.48 12.26%
Unlock
2027
-3.08 11.49%
Unlock
2028
-3.30 7.14%
Unlock

Based on analysts' sales estimates for 2024, the Keros Therapeutics Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

277.84
Unlock
and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of
1,202.04
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 236.52 99.73%
2024
277.84 17.47%
Unlock
2025
40.06 85.58%
Unlock
2026
10.28 74.33%
Unlock
2027
11.63 13.06%
Unlock
2028
2.15 81.50%
Unlock

P/S ratio

Current 1,023.28 99.11%
2024
1,202.04 17.47%
Unlock
2025
173.32 85.58%
Unlock
2026
44.49 74.33%
Unlock
2027
50.30 13.06%
Unlock
2028
9.31 81.50%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today